



# Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer

Filippo Pietrantonio, MD<sup>1,2</sup>; Rosalba Miceli, PhD<sup>1</sup>; Alessandra Raimondi, MD<sup>1</sup>; Young Woo Kim, MD, PhD<sup>3</sup>; Won Ki Kang, MD<sup>4</sup>; Ruth E. Langley, MD, PhD<sup>5</sup>; Yoon Young Choi, MD<sup>6</sup>; Kyoung-Mee Kim, MD, PhD<sup>4</sup>; Matthew Guy Nankivell, MSc<sup>5</sup>; Federica Morano, MD<sup>1</sup>; Andrew Wotherspoon, MBBCh<sup>8</sup>; Nicola Valeri, MD, PhD<sup>8,9</sup>; Myeong-Cherl Kook, MD, PhD<sup>3</sup>; Ji Yeong An, MD, PhD<sup>4</sup>; Heike I. Grabsch, MD, PhD, MBA<sup>10,11</sup>; Giovanni Fucà, MD<sup>1</sup>; Sung Hoon Noh, MD, PhD<sup>6</sup>; Tae Sung Sohn, PhD<sup>4</sup>; Sung Kim, MD<sup>4</sup>; Maria Di Bartolomeo, MD<sup>1</sup>; David Cunningham, MD<sup>8</sup>; Jeeyun Lee, MD<sup>4</sup>; Jae-Ho Cheong, MD, PhD<sup>6</sup>; and Elizabeth Catherine Smyth, MD<sup>11</sup>



# Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer

Filippo Pietrantonio, MD<sup>1,2</sup>; Rosalba Miceli, PhD<sup>1</sup>; Alessandra Raimondi, MD<sup>1</sup>; Young Woo Kim, MD, PhD<sup>3</sup>; Won Ki Kang, MD<sup>4</sup>; Ruth E. Langley, MD, PhD<sup>5</sup>; Yoon Young Choi, MD<sup>6</sup>; Kyoung-Mee Kim, MD, PhD<sup>4</sup>; Matthew Guy Nankivell, MSc<sup>5</sup>; Federica Morano, MD<sup>1</sup>; Andrew Wotherspoon, MBBCh<sup>8</sup>; Nicola Valeri, MD, PhD<sup>8,9</sup>; Myeong-Cherl Kook, MD, PhD<sup>3</sup>; Ji Yeong An, MD, PhD<sup>4</sup>; Heike I. Grabsch, MD, PhD, MBA<sup>10,11</sup>; Giovanni Fucà, MD<sup>1</sup>; Sung Hoon Noh, MD, PhD<sup>6</sup>; Tae Sung Sohn, PhD<sup>4</sup>; Sung Kim, MD<sup>4</sup>; Maria Di Bartolomeo, MD<sup>1</sup>; David Cunningham, MD<sup>8</sup>; Jeeyun Lee, MD<sup>4</sup>; Jae-Ho Cheong, MD, PhD<sup>6</sup>; and Elizabeth Catherine Smyth, MD<sup>11</sup>



**FIG 4.** Kaplan-Meier curves of overall survival according to treatment (surgery plus chemotherapy v surgery only) and microsatellite-instability (MSI) status (MSI-high v microsatellite stable [MSS]/MSI-low) in (A) whole trial population and (B) MAGIC and CLASSIC trials only.